NCT00830154View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2011

Conditions
Stuttering
Interventions
DRUG

pagoclone

0.30 mg BID, 0.60 mg BID

OTHER

placebo

placebo

Trial Locations (1)

Unknown

Indianapolis

Sponsors
All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Endo Pharmaceuticals

INDUSTRY